This is a prospective observatory clinical study, aiming to establish and validate venous thromboembolism risk model in Chinese advanced non-small cell lung cancer.

VTE has high incidence in lung cancer and increases the mortality. Appropriate preventive measures contribute to 50% increase of incidence. The investigators are to investigate the VTE in advanced non-small cell lung cancer and delineate the risk factors to establish a VTE risk model system helping clinicians to differentiate VTE high risk population and apply early prevention in order to reduce the incidence of VTE.

Inclusion Criteria:

• Age ≥ 18 years at the time of screening.
• Eastern Cooperative Oncology Group performance status of ≤ 2.
• Written informed consent obtained from the patient.
• Histologically and cytologically documented Stage 3B-4 lung cancer (according to Version 8 of the International Association for the Study of Lung Cancer Staging system).
• Patients with stage 1 to 3, who undergo radical therapy with disease free survival (DFS) >12 months.
• Willingness and ability to comply with scheduled visits and other study procedures.

Exclusion Criteria:

• History of another primary malignancy except for malignancy treated with curative intent with known active disease ≥ 5 years before date of the informed consent.
• Without signed informed consent.
• Unwillingness or inability to comply with scheduled visits or other study procedures.
• Previously diagnosed with VTE before signing informed consent.

Patients diagnosed with advanced staged lung cancer with written informed consent.